Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
October 31, 2024
Earnings Call Speaker Segments
Lawrence Keusch
executiveHello, everyone, and thanks for joining the Teleflex Incorporated Third Quarter 2024 earnings conference call this morning. You can find the press release and slides that go with this call on our website, teleflex.com. Just a note that a replay will also be accessible on our website. For those who want to listen to the replay, please check our press release from this morning for the specifics. On the call with us today are Liam Kelly, our Chairman, President, and Chief Executive Officer, along with Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom will give prepared remarks, and after that, we'll take your questions in a Q&A session. Before we get started, I want to point out that certain topics we'll discuss on this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website. We want to warn you that these statements are indeed forward-looking in nature and come with risks and uncertainties, so actual events or results could differ materially. The factors that might cause actual results or events to differ materially include, but are not limited to, those mentioned in our press release today, along with our filings with the SEC, including our Form 10-K, which is available on our website; now I'll hand the call over to Liam for his remarks.
Liam Kelly
executiveLarry, thank you — and good morning, everyone. On this call, we'll review how we did in the third quarter, highlight some commercial points, and share an update on our view of how financial guidance is taking shape for 2024. Teleflex generated revenues of $764.4 million in the third quarter, an increase of 2.4% versus the prior-year period on a GAAP basis, and 2.2% higher on an adjusted constant currency basis. Third quarter revenues came in slightly below the $765-$770 million range we had guided to, and that mirrors unforeseen weakness in our OEM business. Adjusted earnings per share in the third quarter was $3.49, a decline of 4.1% from the prior year, but still comfortably ahead of expectations, driven by strong margin performance, and Tom will cover that in more detail later on this call. Let's take a closer look now at third quarter revenue results. I'll begin by going through revenues for our geographic segments in the third quarter. Unless I say otherwise, every growth rate I cite is on an adjusted constant currency basis. Americas revenues were $433.3 million, a rise of 1.5% year-over-year. Those of you who track Teleflex know that prior year MSA revenues were booked in the Americas, and that impacted growth by approximately 510 basis points in the third quarter. EMEA revenues of $150.2 million increased 3.9% versus a year earlier. That growth continues to be fueled by our targeted strategy of expanding where Teleflex products are geographically available and raising utilization in Europe. Now turning to Asia, revenues totaled $98.3 million, up 5% from a year earlier. The quarter was largely impacted by ongoing soft performance in South Korea resulting from the continuing effect of the doctor's strike. We estimate the doctor's strike cut our APAC growth by roughly 2%. Looking forward, the doctor's strike continues, which means headwinds will likely remain for the balance of 2024. Let's now talk about our third quarter revenues by global product category. Commentary on global product category growth for the third quarter will be on a year-over-year adjusted constant currency basis, starting with vascular access. Revenue increased 6.3% from a year earlier to $180.9 million; during the quarter, growth was driven by our broad vascular access portfolio, including our peripheral and central access products. Notably, and as we had anticipated, global PIC revenue grew strong double digits as we continue executing on our strategy to expand usage of Teleflex products. Turning to interventional, revenue was $149.9 million, up 11.4% versus a year earlier; the broad portfolio performed well in the quarter. We still expect a greater contribution from intra-aortic balloon pump revenues in the fourth quarter. Moving on to anesthesia, revenue increased 3.4% year-over-year to $101.1 million. Growth was led by intraosseous products, hemostatic products, and single-use laryngeal masks; within our surgical business, revenue was $111.7 million, down 1% from a year earlier. When you look at the underlying trends across our core surgical franchise, they stayed solid. Growth in our biggest franchises was led by instrumentation and chest drainage, but a tough year-over-year comparison in our ligation portfolio offset that. During the quarter, Titan stapler's growth trends gave us reason for optimism—they improved versus the prior quarter and, as we had expected, delivered robust double-digit gains compared with a year earlier. In line with our approach, we keep proctoring surgeons and continue rolling out our buttress kit after the launch that took place earlier in 2024. The sequential improvement is encouraging, and we still view this product as a driver of growth in the years ahead. Turning to interventional urology, revenue came in at $83.4 million, up 13.3% from the same period a year ago. As anticipated, the increase was powered by Barrigel revenue after the October 2023 acquisition of Palette Life Sciences. UroLift growth, as expected, faced pressure from ongoing difficulties in the office site of service. OEM revenue rose 0.1% versus a year earlier, reaching $82.6 million, which was weaker than we had anticipated; a large customer recently informed us of its decision to vertically integrate a component that we have supplied, and that has caused us to lose this revenue stream. Beyond that, we have begun to observe certain customers postponing orders as their attention increasingly turns to inventory management. Going forward, we know of no market share loss, and we have deliberately expanded manufacturing capacity for our thin-walled microcatheters, which rank among the fastest-growing segments for OEM. Considering how the markets we serve keep expanding, we would expect the weakness in OEM revenue growth to prove temporary, though it is unlikely to be worked out during 2024. Other revenue for the third quarter fell 28.3% compared with a year earlier, landing at $54.8 million. This year-over-year revenue decrease stems mainly from the planned December 2023 exit of the MSA by Medline. That wraps up my remarks on third quarter revenue performance. Moving to a few commercial and clinical updates, beginning with news on Palette, the acquisition we made most recently. We have owned Palette Life Sciences for roughly one year now, and I am happy to say that this acquisition keeps performing better than we had expected. Barrigel keeps building momentum in the U.S. with solid sequential revenue growth; our marketing strategy is succeeding, and we keep converting urologists and radiation oncologists to rectal spacing thanks to the compelling clinical data and the ease of use of Barrigel. Over a longer horizon, we identify multiple potential opportunities to broaden the indications for our NASHA product platform; for instance, the first patient was enrolled not long ago in a study of Barrigel for men with cancer following surgical removal of the prostate. This trial will examine rectal spacing with Barrigel in patients receiving hyperfractionated post-prostatectomy radiation therapy at sites across the United States and one site in Australia. The study's goals are to demonstrate that Barrigel rectal spacer is a safe and effective option that reduces prostate radiation side effects in this patient group. Depending on how risk groups are divided among low, medium, and high prostate cancer recurrence after radical prostatectomy, the range spans 16% to 46%. Given how strong the third quarter was, our 2024 revenue outlook for Palette is rising to $73-$75 million, up from the prior range of $70 million to $72 million. This increased guidance reflects both the third-quarter results and revised fourth-quarter assumptions. Palette continues to exceed our expectations, but UroLift has not yet stabilized in the United States. Since UroLift remains under pressure, our fourth-quarter assumptions incorporate the third quarter's results, the typical seasonal pattern at year-end, and the impact of the recent hurricanes plus saline shortages experienced early in Q4; consequently, our guidance for full year 2024 interventional urology total revenue now assumes approximately 5% growth, down from the 7.5% growth we had previously assumed. Now turning to the intra-aortic balloon pump market. In the United States, code activity continues to run above our historical levels, which follows a May 8th letter the FDA sent to healthcare providers regarding pump safety and quality concerning our main competitor in the intra-aortic balloon pump market. Our view remains unchanged that the largest incremental opportunity for Teleflex will be in the United States market, after the agency recommended that healthcare facilities move away from using competitive devices and seek alternatives where possible. We also expect further share gains in Asia, driven by the team's solid execution over the last couple of years.
Liam Kelly
executiveOn the EU side, the notified body covering our biggest rival said recently that its intra-aortic balloon pumps will stay under a temporary CE mark suspension through July 1st, 2025. Our assumption remains that no significant share movement will occur in Europe. We'll keep a close watch on the market and stand ready to address customer needs if they come up. Notably, we've successfully scaled up production capacity for pumps and catheters to serve customers looking for another supplier. Through 2024, we'll keep growing that manufacturing capacity, adjusting it carefully based on demand signals. Considering the different balloon pump market dynamics worldwide, our fourth quarter of 2024 outlook is unchanged from earlier guidance. Last, a clinical update. Within our surgical business, we keep building the body of clinical evidence supporting the Titan SGS stapler as safe and effective for patients having laparoscopic sleeve gastrectomy. In August, we shared news of a published propensity matching review of retrospective data. According to this single-center study, the Titan SGS stapler allows consistent gastric pouch formation with fewer variations, delivering potentially better clinical outcomes and notable procedural efficiency versus traditional surgical staples. The study demonstrated that using the Titan SGS stapler to streamline an efficient stapling process correlated with fewer 30-day readmissions, particularly those tied to nausea and vomiting, and this was statistically significant. Median operative time with the Titan SGS stapler came in eight minutes shorter than multi-fire staplers, which was statistically significant too; that's a key efficiency data point as hospitals look to optimize OR time. Furthermore, patients in the Titan SGS stapler cohort had a greater likelihood of being discharged within 24 hours following surgery versus multi-fire staplers. The Titan SGS stapler remains the first and only single-fire surgical stapler built and indicated for sleeve gastrectomy pouch creation, and the sole surgical stapler with FDA clearance for this specific indication. We'll keep prioritizing support for the Titan SGS stapler through expanded clinical data. That wraps up my prepared remarks. Now I'd like to hand the call to Tom for a more detailed review of our third quarter financial results. Tom.
Thomas Powell
executiveThanks, Liam, and good morning. Since we already went over how the company's revenue performed, I'll start with margins. Adjusted gross margin for the quarter came in at 60.8%, which is up 140 basis points from the same period a year ago. That year-over-year gain was mainly driven by the favorable gross margin impact from terminating the MSA and from acquiring Palette Life Sciences, along with favorable price, and it was partly offset by manufacturing inefficiencies and ongoing cost inflation, including labor and raw materials. In the third quarter, adjusted operating margin reached 27.3%. The 10 basis point increase over last year was mostly the result of flow-through from the year-over-year gross margin improvement, partly offset by including Palette Life Sciences operating expenses and investments made to grow the business. Net interest expense came to $18.8 million for the third quarter, up from $15.7 million in the prior year period. That year-over-year rise in net interest expense reflects the funding impact from the Palette Life Sciences acquisition and from share repurchases made in the third quarter. Our adjusted tax rate for the third quarter of 2024 was 13.6%, versus 8% a year earlier. The year-over-year rise in our adjusted tax rate stems mainly from additional costs tied to enactment of European Pillar Two tax reform, prior year non-recurring discrete benefits that did not repeat this period, and non-recurring discrete detriments incurred in the third quarter. At the bottom line, adjusted earnings per share for the third quarter was $3.49, down 4.1% from the prior year. The year-over-year decline in earnings per share reflects dilution from the Palette Life Sciences acquisition and the associated incremental borrowings, the MSA termination, and a higher tax rate. Now turning to a few balance sheet and cash flow highlights. Cash flow year-to-date remained solid. Cash flow from operations across the nine months was $435.6 million, versus $372.4 million in the prior year period. That $63.2 million increase came primarily from favorable operating results, a reduction in cash outflows from inventories as we keep moderating inventory levels, and proceeds from terminating a pension plan. Higher tax payments partly offset the rise in net cash provided by operating activities. On the balance sheet, at the close of the third quarter, our cash equivalents and restricted cash equivalents balance stood at $277.8 million, including $34 million of restricted cash equivalents tied to the 2024 pension termination, compared with $222.8 million as of year-end 2023. Net leverage at quarter-end was roughly 1.7 times. I'll now give an update on our $500 million share repurchase authorization, which includes a $200 million accelerated share repurchase program. Under the ASR terms, which started on August 2nd, 678,000 shares were bought back during the third quarter, representing 80% of the $200 million aggregate under the program. We expect to finish the ASR in the near term. Beyond that, we’ve got $300 million remaining under our share repurchase authorization right now, and we’ll stay opportunistic about buybacks going forward. With robust cash generation as our foundation, returning capital to shareholders continues to be a key part of how we allocate capital in a disciplined way. Now to our revised financial guidance for 2024. Under our updated 2024 outlook, we assume adjusted constant currency revenue growth of 3.5%-4%, down from 4.25%-5.25% before. Keep in mind this range leaves out the $13.8 million negative effect from the Italian measure we talked about on our second quarter earnings call, plus a $4 million FX-related headwind. Our guidance now captures year-to-date performance and fourth quarter dynamics, among them weaker-than-expected revenue in both our OEM business and our interventional urology business. As Liam said earlier, we still haven’t seen UroLift stabilize; on top of that, we’ve also seen procedure cancellations early in the fourth quarter stemming from disruption caused by recent hurricanes across the southern United States, along with the effect of saline shortages on elective procedures. On a GAAP basis, we anticipate reported revenue growth of 2.9%-3.4% in 2024, which implies a dollar range of $3.061 billion-$3.076 billion. If you exclude the Italian measure’s impact, we anticipate reported revenue growth of 3.4%-3.9% in 2024, for a dollar range of $3.075 billion-$3.090 billion. This revenue range — GAAP revenue in particular, excluding the $13.8 million impact from the true-up of the Italian measure — serves as the anchor for our 2024 guidance. For modeling purposes, the 2024 outlook incorporates an assumption of $809-$824 million in revenues for the fourth quarter, which represents growth of 4.6%-6.5% year-over-year on an adjusted constant currency basis, excluding an expected FX headwind of roughly $1 million. We’re lifting the low end of our 2024 gross margin guidance by 25 basis points, to a range of 60.5%-61%. Our gross margin guidance mirrors the operating performance for the first nine months of 2024, along with our expectation of a bigger foreign exchange headwind in the fourth quarter and accelerated capital equipment sales in the fourth quarter from intra-aortic balloon pumps. The capital component of pumps dilutes our corporate gross margin slightly. Even so, we expect the margin profile to get better down the road as we sell disposables, or catheters, which carry a more favorable margin profile; we’re also lifting the low end of our operating margin guidance by 25 basis points, to a range of 26.75%-27.0% for 2024. Our guidance mirrors the flow-through of gross margin and the positive impact of restructuring, offset by including operating expenses for Palette Life Sciences and investments to grow the business. Turning to items below the line, we now expect net interest expense of approximately $78 million for 2024 versus $81 million previously. The lower net interest outlook mainly mirrors debt paydown as well as lower interest rate expectations. Our tax rate for 2024 is now expected to fall in the range of 12%-12.5% versus the prior guidance of approximately 12%. Our 2024 tax rate takes into account both the actual results booked so far this year and what we anticipate for the fourth quarter. Now, on the earnings side, we're lifting the bottom end of our guidance by $0.10, and that reflects how the third quarter performed. As a result, our expectation for 2024 adjusted earnings per share now sits in a range of $13.90-$14.20. And last, for 2024 we're assuming 47.1 million average weighted shares, which takes into account the $200 million ASR that began in the third quarter. That wraps up my prepared remarks. At this point I'd like to hand it back to Liam for some closing commentary.
Liam Kelly
executiveThank you, Tom. To wrap up, I want to emphasize three main points from Q3 of 2024. To begin with, while we did face certain revenue challenges during the third quarter, the breadth of our portfolio and our worldwide presence worked in our favor. During the quarter, we achieved growth in gross margin compared with the same period last year and lifted our operating income. We kept our attention squarely on execution. Our margins are still solid, and we increased the lower bound of our adjusted 2024 EPS guidance range. Notably, our outlook for adjusted earnings per share in 2024 accounts for roughly $0.85 in headwinds versus the prior year, which includes dilution stemming from the MSA termination and the Palette Life Sciences acquisition, higher taxes largely driven by the Pillar Two minimum tax, and foreign exchange. Once those headwinds are adjusted for, underlying adjusted constant currency earnings per share growth compared with last year comes to about 9% at the bottom end of guidance and 11% at the top end. Next, cash flow results have stayed robust in 2024, with $436 million in cash flow from operations across the nine months, which is $63 million above the equivalent period a year earlier. We are still positioned to deliver more than $500 million in cash flow from operations for the entirety of 2024. After subtracting capital expenditures aimed at fueling growth, that leaves roughly $400 million in free cash flow. This solid cash generation gives us a firm base for carrying out our disciplined capital allocation approach, which includes reinvesting in the business, pursuing inorganic growth possibilities, returning capital to shareholders, and paying down debt. Finally, we will keep our focus on the strategy aimed at delivering sustainable growth. Palette is exceeding what we anticipated; we are making progress on the intra-aortic balloon pump and catheter opportunity, and Titan is producing dependable growth. We remain on our path to reshape our portfolio, to generate growth, and we will carry out the expansion of our internal innovation engine while chasing inorganic opportunities, M&A included; that brings my prepared comments to a close. At this point, I would like to hand the call back to the operator so we can move to questions and answers.
Patrick Wood
executiveGreat. I really appreciate you guys fielding the questions. I have one thing to ask, and then a follow-up after that. The first item concerns the revenue reduction on the top line — nice work on the gross margin front, by the way — but regarding the top line, that sales cut, OEM, I mean, based on my own calculation at least, appears to account for approximately half of it. I believe you mentioned this during the prepared remarks. Would I be correct in thinking the remaining half is mostly driven by weather and the IV solution side? Does that sound right, or is there another factor at play?
Thomas Powell
executiveNo, there are two categories, and you simply placed them incorrectly, Patrick. So when we review the quarter, I'd describe our feelings about OEM's results as disappointing. That said, aside from OEM, every other part of the business did quite well during the quarter. Despite what OEM dragged down, we still landed modestly under the guidance range we'd given of $765-$770. And we're especially pleased, as you noted, about the margin expansion, how earnings per share came in, and clearly the robust free cash flow, which positions us well to carry out our capital allocation strategy. Now, turning specifically to what you asked about those categories for the full year, there are two of them, as you mentioned: OEM and interventional urology. The overall shift at the low end of guidance, Patrick, comes to roughly $22 million. OEM accounts for the bigger piece, and two things are behind it. First, there's the vertical integration of a customer order plus orders being pushed out because of inventory management. Together, those amount to about $14 million across the full year, and most of that stems from an unexpected vertical integration that caught us off guard. The remaining portion traces to interventional urology. Palette keeps delivering strong results and we're genuinely pleased with how it's doing, but our earlier guidance had baked in stronger UroLift trends for the fourth quarter, and those haven't materialized. What our updated guidance does assume is typical seasonality, though it doesn't assume improved trends, and it also factors in the Q4 effects from the hurricanes and the IV saline shortage hitting procedures. That category's overall impact, Patrick, comes to roughly $8 million for the full year, which reflects Palette's better performance alongside UroLift taking about an $11 million hit. So those are the full-year categories. For the quarter itself, OEM's impact was roughly $7 million. If you set OEM aside, we'd have landed comfortably inside the ranges we'd given.
Patrick Wood
executiveThat covers quite a bit. I appreciate it. Now, to follow up on that. Regarding what's happening with the balance sheet, you clearly talked at our conference, and on a few other occasions, about the possibility that there might be some smaller, bolt-on M&A. How do you view the relationship between completing the remaining $300 million in buybacks and pursuing bolt-on M&A? In what way do you weigh those two opportunities?
Thomas Powell
executiveThe positive here, Patrick, is that our balance sheet is extremely strong. At present, net leverage stands at 1.7 times. During the prepared remarks, you saw that free cash flow from operations came to $435 million, which is $63 million higher — a remarkable free cash flow result that leaves us quite confident we can accomplish both things. Within our share repurchase plan, $300 million is still available, and we plan to deploy that when opportunities arise. The M&A landscape looks quite favorable at the moment, and we are pursuing several private assets in the market. We stay active. When we might bring an asset aboard is uncertain, but I want the investment community to understand that we are putting in serious effort. Just to clarify, the free cash flow figure I mentioned was free cash flow from ops; the assets we're evaluating fall within the catalog. Our attention is squarely on that call point — the intensive care call point, emergency medicine — along with tokens in other areas of the business. Discipline will be maintained, and we remain focused on assets that are non-earnings per share dilutive, which we hope to add to the Teleflex family. So we're active on that front, and we would also plan to keep up our capital allocation efforts on the share repurchase side of returning capital to shareholders.
Matthew O'Brien
analystGood morning, and I appreciate you taking my questions. I'm hoping to get a little more detail beyond what was discussed in the previous question. Liam, regarding the pressure from OEMs, should we expect that same figure of approximately $14 million to still be felt during the first half of next year? Then, on the topic of UroLift, is the weakness genuinely still limited to the physician's office setting, or are you starting to observe it appearing in other weaker areas, such as hospitals or ASCs? The reason I ask is that, from what I understand, the physician's office business is fairly small at this stage. I also have one more question after this. Thank you.
Liam Kelly
executiveYes, thank you, Matt. Regarding the OEM, like I said, the bulk of that $14 million is tied to vertical integration. To be honest, that caught us off guard. We've operated this specific business for several years, and we didn't anticipate this customer—one of our biggest—deciding to take it in-house. That situation will persist through Q3 of next year. So regrettably, it's going to keep going. On the destocking front, we'll keep a close eye on it alongside our customers' inventory management, and we'll decide how to handle it as the year progresses. To answer what you asked, Matt, it remains the office side of service. The office side of service is facing enormous difficulties. We're clearly entering the last year of reimbursement adjustments, and it'll be a relief once those changes are behind us. For UroLift in 2025, that's going to mean roughly another 6% hit to the reimbursement rate. Once that's done, the declines in office-based service reimbursement should come to an end, so ideally we'll start seeing things level off after that.
Matthew O'Brien
analystUnderstood. And I'm not asking for 2025 guidance right now. What I was really after is a bit of a range for how we should frame next year, since you've got what sounds like a $10 million OEM headwind, while Barrigel is performing better and PICC's are doing great, and other areas are doing well too. So I'm just wondering whether we can think about how all of those things, along with the MSAs going away, might shape what we consider for the underlying business next year, with top-line growth expected to be mid-single digits; and can operating margins return to the level you saw in 2021? Thanks.
Liam Kelly
executiveSo, Matt, clearly, this is the third quarter call. So we'll cover the 2025 guidance when we reach our Q4 call, which is our next earnings call, obviously. So if you don't mind, I'll cover that when we get to that earnings call.
Jayson Bedford
analystMorning. Appreciate you fielding these. Perhaps only two from me. Several figures have been circulating regarding the OEM situation. So, how much yearly revenue did that lost OEM client represent? And I'm sorry if someone already brought that up.
Liam Kelly
executiveThat's fine, Jayson. Essentially, it's a $14 million hit to our guidance for the entire year, and most of that stems from the vertical integration. That's the precise figure. We recorded $7 million of it during Q3, and there's another $7 million expected in Q4; so $14 million altogether across the full year tied to OEM. All right. All right. Thank you.
Jayson Bedford
analystRegarding how things stand with the balloon pump, was there any effect during 3Q? And have the basic assumptions you shared during the second quarter call been modified in any way?
Liam Kelly
executiveOur basic assumptions remain the same. Investors likely know that a competitor of ours received a notice from the FDA telling customers to stop using their pump and look for another option. In the U.S., our quote volume remains robust, and the U.S. is where that focus lies. Since that time, the sole modification is that the competitor's CE mark suspension now runs through July of 2025. Within EMEA, we do not expect any meaningful shift. Our view is still that the bulk of the benefit will arrive in the Americas. So a rise in the interventional access growth rate ought to be visible in Q4, tied specifically to the number of pumps we expect during Q4, and our expectations have not shifted at all. No impact showed up in Q3 for us, which also matches what we had previously expected regarding the balloon pumps. The expectation is that it will land in Q4.
Liam Kelly
executiveOur view hasn't shifted at all since the Q2 call as we head into Q4, Shagun. During that Q2 call we had expected — we raised our revenue guidance by roughly $15 million, and we attributed a big chunk of that to the intra-aortic balloon pumps, so figure more than $10 million landing in Q4. Looking ahead to 2025, we expect that opportunity to stay with us across the first half of 2025, and our assumption there remains unchanged as well. Of course, like I told Matt before, we'll address guidance once we reach our Q4 earnings call, and at that point we'll lay out what we expect the balloon pumps' impact to be; as I've already mentioned, we don't anticipate much of an effect within Europe, and in Asia-Pacific we keep gaining share.
Matt Taylor
analystThanks once more for fielding this. I wanted to circle back on the balloon pump projection and get a sense of which signposts you're watching regarding the order activity you've already booked, plus how you'd estimate the potential upside should your competitor's difficulties stretch on. So we'd really appreciate additional detail on the orders received so far and your approach to gauging what next year's upside might look like under those circumstances.
Liam Kelly
executiveAs mentioned previously, the orders visible for Q4 exceed $10 million. And, as I noted a bit earlier, we continue to expect the competitor to remain absent from the market through the first half of next year. The wildcard, Matt, is whether they stay away beyond that point, since that scenario would open up a longer-term opportunity. That's essentially the benchmark, and we'll evaluate it as things unfold. So we expect them to be absent from the market until at least the first half of 2025, and we'll be pursuing that opportunity. Order rates have persisted — sorry — quotation rates have persisted strong all the way through Q3. Naturally, they crested late in Q2, yet they've stayed strong across Q3 and into Q4; therefore we'd expect that at minimum through the first half of next year, this represents an opportunity for Teleflex.
Matt Taylor
analystAll right. May I inquire about what the weather and IV Solutions have done to you? Could you describe the magnitude observed up to this point? Should we anticipate that IV Solutions will carry over past Q4, or is this merely a brief, passing effect?
Larry Biegelsen
analystHello. I appreciate you fielding the question. Tom, here's one about finances for you. In what way ought we to consider reducing debt, and what amount of interest expense might you lower in the coming year? It appears to be a solid chance when compared with the $78 million guidance figure for this year. And I had a single additional item.
Thomas Powell
executiveWell, our approach to free cash flow will involve balancing investments of an organic and inorganic nature, together with possibly using whatever remains under the share repurchase authorization, against paying down debt. If we have extra cash past what's needed to expand the business or perhaps buy back shares, then we'd view that as a way to apply cash toward reducing our prepayable debt. So next year we intend to genuinely balance those three equations.
Larry Biegelsen
analystUnderstood. Then, Liam, from what I understand, the intraosseous offering has served as quite a robust engine of growth for your team. Yesterday a rival made public that it had received approval for a brand-new device. I realize it's still early, but I'm simply interested in how you view the competitive landscape in that area, since it represents a large and significant product for your company. Thank you.
Liam Kelly
executiveYes. Thank you, Larry. Naturally, we are conscious of the rival dynamics in the market; this competitor had been present in the market more than 18 months back, and we managed to counter their attempts to shift customers. The product enjoys tremendous loyalty among customers. It is the marketplace's first intraosseous device and has kept delivering very strong results for us. We have not sat still knowing that this competitor is entering the market, and we keep innovating on our product. And only recently, we introduced a disposable intraosseous product in a tray format for ease of use so that we can keep converting the hospital market in the United States. That launch has performed extremely, extremely well. So we still believe we have considerable differentiation in the market, and we are watching the situation very carefully.
Anthony Petrone
analystAppreciate you fitting us in. I've got a few on urology, then one about Asia-Pacific. Could you give us an update on Palette and UroLift? Those sales teams have been combined at this point. My understanding is the complete integration runs until the close of 2024, and it seems they can now go out and sell a bag. Perhaps you could update us on how Barrigel has been folded in with UroLift, and whether synergies are showing up on either or both sides of that portfolio? Also, the announcement made today regarding post-radical prostatectomy — looking forward, what does that opportunity represent for Barrigel? Then I'll ask one about Asia-Pacific. Thank you.
Liam Kelly
executiveYes. Thank you, Anthony, for asking. Palette's integration is essentially complete. It's been ours for close to a year now, and the product's performance has made us extremely pleased. As we said in today's announcement, we found ourselves able once again to raise guidance for Palette. As you may remember, we started the year with an expectation of $66 million-$68 million, and today our guidance range sits at $73 million-$75 million for Palette Life Sciences. And investors are aware that Palette's gross margins are in fact superior to those on UroLift. The integration is essentially complete; there's a small amount of cross-training still to wrap up during the fourth quarter, but we expect to get that finished; when we bought Palette Life Sciences, we actually didn't put a halo effect for UroLift into our model. The halo we have observed has in fact gone to the Barrigel product on the Palette side, since we now have additional sales reps in the field selling that product. So that's what has produced stronger performance on the Palette side. And as I mentioned earlier while answering Matt's question, clearly, UroLift remains challenged on the office side of service. So turning to post-radical prostatectomy, which was the other portion of what you asked, Anthony. This represents a meaningful opportunity for Teleflex and for the Palette portfolio. In anywhere from 10%-50% of men undergoing a radical prostatectomy, the cancer comes back. So at the midpoint, that's roughly 30% of an additional market, or approximately $100 million of market opportunity. What makes this opportunity so intriguing to us is that Barrigel will be the sole spacing technology applicable in this area, thanks to the NASHA compound and the way it functions. No other spacing technologies will be effective in this particular application. So we find that encouraging. We've enrolled the first patient. It'll take roughly a year and a half, from enrolling all of the patients through writing up the study and submitting it to the FDA, to secure the expanded indication, and we're very much looking forward to obtaining that indication and serving that $100 million spacing market, where patients today lack access to spacing if they're undergoing radiation therapy post-radical prostatectomy.
Ravi Misra
analystMorning, everyone. Ravi Misra here. I've got a pair of questions — the first about IABP, the second about M&A. On the first one, regarding IABP, you mention $10 million of line of sight for the fourth quarter. Can you walk us through how much of that falls under capital versus consumable? And within that cohort, what sort of long tail do you anticipate coming from the consumables side?
Liam Kelly
executiveSure, Ravi. What I'd say is that the bulk of it sits in capital, in the United States. Consumables will come along afterward, across some span of time. When you consider the market as a whole — the worldwide market for intra-aortic balloon pumps and catheters — it splits roughly evenly. Pumps account for one half of the market, and catheters account for the other half. On the remaining piece of your question, about what would come later, my view is that going forward, pairing the manufacturer's catheter with the manufacturer's pump offers a compelling benefit. Among most customers in the United States today, the majority will choose fiber optic. When a Teleflex catheter is paired with a Teleflex pump, that fiber optic capability is there for you. Should you pair a competitor's catheter with our pump, that fiber optic advantage is lost. So in our view it's compelling that customers will pair our catheter with our pump.
Ravi Misra
analystUnderstood. And I'd assume, with the FDA handling things the way it is, that the consumable tail would be stretched out somewhat further. Then second, regarding M&A, you mentioned, I believe, assets that don't dilute EPS. So does that suggest your willingness to accept EPS dilution from M&A has come down somewhat? It sounds as though the market could be loosening up, and valuations could be rising somewhat. That comes across as somewhat different from your earlier comments. Should we view the repo here as something that lifts earnings enough to offset that dilution, or that makes M&A more or less neutral?
Liam Kelly
executiveSo, Ravi, about the environment. I'd disagree somewhat that valuations are climbing. What I believe we're observing in the market is that valuations have at last begun to moderate, and they've been moderating for more than the past 6 months. Whatever occurs in the public markets needs time before it filters through to the private markets; and second, I think given that shift in valuation, clearly, with rates having improved, it becomes far more attractive to acquire an asset that won't dilute EPS. Clearly, our standards remain the same; we seek assets that add to our top-line growth. And beyond that, we seek assets whose gross margin is at minimum on par with ours, if not better, and that will keep adding over time. And we will reach op-margin accretion within a sensible timeframe. What I'm getting at, I suppose, is that assets exist that satisfy every one of those requirements and likewise don't dilute EPS.
Dave Turkaly
analystGood morning to you. Liam, one thing I'd like to verify — when it comes to the OEM business, is it mainly located in the Americas?
Liam Kelly
executiveYes, Dave, the Americas account for the overwhelming share of that revenue. You've got that right.
Dave Turkaly
analystThanks. Next, I'd like to ask about Manta. Could you provide some sense of its current performance—perhaps a growth rate, and what you're observing regarding the procedures it supports?
Liam Kelly
executiveSure. Regarding procedures: to begin with, Manta keeps gaining ground in the market. Among large bore closure devices available today, it's the sole single-shot option. TAVR and EVAR are the procedures where it's applied. During the last 12 months, while we kept expanding within TAVR, our attention has now shifted toward achieving that same expansion in EVAR. What we've observed is that the EVAR portion isn't as sensitive to price as the TAVR portion is. As a result, pricing for us in the EVAR segment has been considerably better; so we keep expanding, Dave, and the product keeps delivering.
Craig Bijou
analystMorning, everyone. Appreciate you taking my question. I had one about IABP, and then a follow-up regarding OEM. So, Liam, regarding the orders you're seeing or what you're projecting for Q4, I'm curious whether you have visibility into if those orders represent a typical replacement cycle for the pumps. So have they hit the end of their useful life? Or are you actually seeing hospitals move away from the competitor's pumps?
Liam Kelly
executiveWell, the standard replacement of our own pumps is included in that figure, but we're also seeing the uplift really being driven. That's our typical course of business, Craig, the conversion. But we are seeing accounts converting entirely away from the competing product. I think that answers your question, and we are seeing that.
Craig Bijou
analystYeah. My apologies — I suppose I didn't phrase that well. What I'm really asking about is the replacement cycle for your competitor. So, are you gaining? When it comes to the orders flowing in and the added revenue you anticipate, does that stem from hospitals shifting away from your rival, or is it simply you capturing a normal replacement cycle? Yeah.
Liam Kelly
executiveFair enough, Craig. My apologies for that; what we observe is a combination of both. As pumps reach the point where they need to be replaced, we're securing those replacements; beyond that, we're also seeing entire systems where pumps get swapped out that, in certain cases, are under two years of age.
Craig Bijou
analystUnderstood, that helps. Then, as a quick follow-up regarding OEM — if the $7 million you mentioned is excluded, my sense is growth for this quarter would come in at 9%. So what's the right way to view how that business grows? Should we call it high single digits? Or is it slow-to-mid single digits? Any framework for thinking about what normal growth looks like for that underlying OEM business?
Liam Kelly
executiveYeah. Clearly, integration will have an effect during 2025. Once you move past Q3 of next year and the vertical integration, the OEM business outlook remains quite positive. That business's typical underlying growth lands in the mid to high single digits; we've had years where the team executed strongly and reached double-digit growth, especially during supply chain disruption. A number of accounts have been converted; we're performing really well in the microcatheter space, and we have capacity. So the positive here, even with this vertical integration, is that we have capacity. We added extensions onto both of two plants. So right now the team is out pursuing new orders, delivering against those orders, and running R&D projects for some of our key customers to build up the order book as we head into 2025. So once 2025 is behind you, Craig, you'll see a normalized growth rate for the OEM business in 2026 and beyond. And that normalized growth would be to the mid- to high-single digits, and in a good year, they'll sneak into the low double digits.
Mike Polark
analystHi, thanks. I apologize in advance—I want to dig a bit deeper into the OEM situation. I'm trying to get a better sense of what drove this customer to bring that work in-house. Are there other items you supply to them as well? After they leave, how big is this account? And on the specific product they're taking back—are you manufacturing that same thing for anybody else? Is there any particular reason they've now chosen to do it themselves? Could that create exposure for that product line with your other buyers? Sorry this is such a tangled question, but I want to grasp the reasoning and the details behind this unexpected development.
Liam Kelly
executiveYeah, Mike, that's a fair thing to ask. This is one product — a significant piece of something that this customer sells under its own brand. We've been making it for many, many years. And the choice was to bring it in-house; we only produce it for this one customer, which answers that part of your question. As for the other part — why did they decide to make it themselves? What our team figures is that they've got an absorption problem at one of their facilities, and they're solving it by taking this in-house. Plus, they already have what's needed at that plant to handle this product. A lot of what we manufacture consists of highly intricate microcatheters and extrusions. This particular item stood out somewhat. It isn't especially intricate, so the company believed it could handle production internally.
Mike Matson
analystYeah, thanks. Just one about Titan and bariatric surgery. So it's good to hear the product performing better, but regarding bariatric surgery, what are you observing when it comes to procedure volumes, any indications of stabilization? And I'm aware it's been going down for some time, so do you think it's just the procedures in general, sorry. Do you think that once we begin to lap those declines, perhaps the market will start to level off?
Liam Kelly
executiveSo as you look ahead, I believe the market will level off. In the current market environment, the downward trend has eased slightly, though volumes are still falling off. But to be frank, Mike, that hardly affects our position. We're going after a $250 million opportunity, and the clinical study we just highlighted on this call shows our product performs better, which means patients leave the hospital sooner. When you look at patients leaving the hospital after just one day, our system shows roughly a 25% difference versus competing technologies. Speed matters too—since only one line of staplers is involved, procedures go quicker, which cuts down on time spent in the operating room. Hospitals weigh that heavily when choosing which technology to adopt, as you can imagine. So things will probably level out, though honestly it makes no difference to us either way. During the quarter, Titan posted strong double-digit growth and also rose from one quarter to the next. That's a positive sign, and it should fuel our expansion over the coming years.
Mike Matson
analystOkay. Got it. Thank you.
Liam Kelly
executiveCheers, Mike.
Kristen Stewart
analystHi. I'd like to zero in for a moment on how gross margin has been doing. Based on what you're guiding to for the whole year, I believe it points to gross margins climbing 100 to 150 basis points across the full year. My understanding is that the MSAs rolling off accounted for roughly 100 basis points. I just want to verify that arithmetic, and then looking forward, should we be factoring in any positives or negatives when it comes to how gross margin will perform next year?
Liam Kelly
executiveSure. As you mentioned, our gross margin guidance has been lifted to a range of 60.5%-61%. The loss of that MSA certainly played a role, and that effect will wrap up during Q4 of this year, since by then it will be baked into our run rate. So when we look ahead to next year, our main focus is on keeping margin expansion moving forward by combining favorable price-to-cost improvement efforts. We also still expect to capture savings tied to restructuring programs, and we intend to apply all of this toward countering inflation. Inflation has been easing compared with where it stood earlier. It remains above pre-COVID levels, but we are beginning to see it cool off. We expect to move beyond certain gross margin pressures experienced during this year, including those tied to losing Palette.
Kristen Stewart
analystAll right. Now let's turn to the chance presented by the intra-aortic balloons. My apologies — I meant the MSA loss, that was a slip of the tongue. Right. So considering the possibility with the intra-aortic balloon pumps and what we're probably going to observe in 2025, should we view you folks treating that as simply dropping down to the bottom line, or might you put some of that upside back into the company?
Liam Kelly
executiveThe way we see it, like I mentioned before, that chance will remain available to us through at minimum the first half of 2025. Depending on how the FDA rules, there's a possibility it extends beyond that point, though we'll evaluate that along the way. On that front, we'd prefer to see a solid share of it reach earnings, yet we'd also want to direct a portion toward growth investments down the road. I believe that represents a balanced way of handling that opportunity, which is what we'd aim for.
Lawrence Keusch
executiveAppreciate that, Mark. And thanks to all of you for being with us on today's call — that wraps up Teleflex Incorporated's third quarter 2024 earnings conference call.
Operator
operatorThat concludes today's call. Thank you all for joining. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.